company insight

Lonza Pharma & Biotech – Capsule Delivery Solutions

Capsule Delivery Solutions, part of Lonza Pharma & Biotech, is the leader in capsule-based solutions and services, proudly offering Capsugel® products. With the largest production and supply chain footprint in the industry, Capsule Delivery Solutions provides the highest quality and deepest regulatory expertise to its 2,000 pharmaceutical customers, globally.

SHL Group details its approach to the challenges of emerging formulations

For more than 100 years, biopharmaceutical companies have relied on the quality, consistency and functional innovations Capsugel® has delivered; today we produces more than 200 billion capsules in over 100 countries.

Building on our history of innovation in polymer science and capsule engineering, Capsule Delivery Solutions continues to launch ground-breaking capsule designs and equipment technologies that are improving drug development and delivery. Whether you’re looking to formulate new products or enhance an existing line, we have the right capsule to help you bring improved products to market faster. With a diverse portfolio including HPMC, Dry Powder Inhalation capsules or specialized clinical capsules, we are a global leader in capsule development and manufacturing, bringing unmatched products and technical support to our worldwide customer base.

Capsule Delivery Solutions Quality 

From the purchase of key raw materials to the manufacturing, packaging and delivering of finished products, Capsule Delivery Solutions works to ensure the safety and quality of capsules we supply to pharmaceutical customers around the world.

As key elements of our quality commitment, Capsugel is investing in Regulatory Compliance Monitoring Programs that anticipates and proactively responds to the continuously evolving global food-safety standards and maintains a robust Quality System, from sourcing of our ingredients to the distribution of our products, that is compliant with all applicable standards.

Capsule Delivery Solutions offers

High quality empty capsules:

  • Immediate release: Coni-Snap® Gelatin, Vcaps® Plus, Plantcaps®
  • Targeted & Modified release: Vcaps® Enteric, DUOCAP®

  • Dry Powder Inhalation capsules: Gelatin: Coni-Snap® Gelatin and Coni-Snap® Gelatin-PEG, HPMC: Vcaps® and Vcaps® Plus

  • Preclinical and clinical development capsules: PCcaps®, DBcaps®

  • Patient Centric capsules: Coni-Snap® Sprinkle
  • Life Cycle Management solutions: Press-Fit®, XPress-Fit®

Innovative and tailored services:

Share this article

Go to article: Home | Trust In Big PharmaGo to article: EditorialGo to article: NSFGo to article: ContentsGo to article: Daiichi JitsugyoGo to article: NewsGo to article: FreudenbergGo to article: The Pharma Industry BriefingGo to article: Fisher Clinical Services Company InsightGo to article: Fisher Clinical ServicesGo to article: The People vs Big Pharma: tackling the industry’s trust issuesGo to article: Scandinavian Health Ltd. Company InsightGo to article: Scandinavian Health Ltd.Go to article: Humira: the highs and lows of the world’s most successful drug Go to article: Wilhelm Haselmeier GmbH & Co KG Company InsightGo to article: Wilhelm Haselmeier GmbH & Co. KGGo to article: Gene therapy: talking smart solutions with Bluebird BioGo to article: Moehs Iberica Company InsightGo to article: Moehs Iberica SLGo to article: A research headache: improving the understanding of chronic migraine Go to article: SensitechGo to article: HOF Sonderanlagenbau Company InsightGo to article: HOF SonderanlagenbauGo to article: Philanthropy in pharma: a look inside the ISPE FoundationGo to article: DelSiTechGo to article: Novel Oral Therapies Are An Unmet Need For Ulcerative ColitisGo to article: PhoenixGo to article: FDA removes key barrier to US biosimilar developmentGo to article: Nipro PharmaPackagingGo to article: Pfizer price hikes: do rare cancer drugs warrant higher prices?Go to article: AlpexGo to article: Head-to-head: competing for the most effective psoriasis drugGo to article: Mecmesin Company InsightGo to article: MecmesinGo to article: Takeda to seek label expansion for Ninlaro in multiple myelomaGo to article: Capsugel Company InsightGo to article: Contract Pharmaceuticals Limited CanadaGo to article: Epilepsy: Zogenix’s ZX008 set for showdown with GW Pharma’s EpidiolexGo to article: EcocoolGo to article: Abiogen PharmaGo to article: Illegal online pharmacies: how endemic are they?Go to article: Global Freight Solutions LtdGo to article: The boom in medical cannabis research is set to continueGo to article: AtoZ-CRO GmbH Company InsightGo to article: AtoZ-CRO GmbHGo to article: Population boom will boost acute stroke market, particularly in ChinaGo to article: Pall BiotechGo to article: Cryo StoreGo to article: Watch Alibaba instead of Amazon in healthcareGo to article: WIKA - Disaster preventionGo to article: AstraZeneca’s Lynparza maintains lead in PARP inhibitor raceGo to article: G.F.Go to article: Erdmann Design SwitzerlandGo to article: CMV presents a serious concern in HIV+ personsGo to article: BEA TechnologiesGo to article: BaxterGo to article: bDMARD therapy: adherence in the first year is key to successGo to article: Pharma Support Services Ltd Company InsightGo to article: Pharma Support Services LtdGo to article: End the struggle: pathways to HEAL the opioid crisisGo to article: LaudaGo to article: AbbVie poised to overtake Gilead as hepatitis C leaderGo to article: ILC Dover IncGo to article: ViiV results show the importance of INIs to future HIV treatmentGo to article: PfanstiehlGo to article: Novartis acquires rights to atopic dermatitis candidate MOR106Go to article: Niconex Medical LtdGo to article: EventsGo to article: Next issue